Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles

Journal of Medicinal Chemistry

Volumn 59, Issue 7, 2016, Pages 3311-3330

  Beesu, Mallesh ^a,b   Caruso, Giuseppe ^a   Salyer, Alex C D ^a,b   Shukla, Nijunj M ^a,b   Khetani, Karishma K ^a   Smith, Luke J ^a   Fox, Lauren M ^a   Tanji, Hiromi ^c   Ohto, Umeharu ^c   Shimizu, Toshiyuki ^c   David, Sunil A ^a,b  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 1 PENTYL 4 (2 TOLYL) 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 1 PENTYL 4 (3 TOLYL) 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 1 PENTYL 4 (4 TOLYL) 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 1 PENTYL 4 (PYRIDIN 3 YL) 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 1 PENTYL 4 PHENETHYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 1 PENTYL 4 PHENYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 1 PENTYL 4,5 DIPHENYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 1 PENTYL 5 PHENYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 2 (2 AMINO 1 PENTYL 1H IMIDAZOL 4 YL)PHENOL HYDROCHLORIDE; 4 (2 AMINO 1 PENTYL 1H IMIDAZOL 4 YL)BENZAMIDE HYDROCHLORIDE; 4 (2 ETHYLPHENYL) 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 (2 METHOXYPHENYL) 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 (2,3 DIMETHYLPHENYL) 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 (2,4 DIMETHYLPHENYL) 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 (2,5 DIMETHYLPHENYL) 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 (2,6 DIMETHYLPHENYL) 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 (3,5 DIMETHYLISOXAZOL 4 YL) 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 (4 AMINOPHENYL) 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 (NAPHTHALEN 1 YL) 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 (NAPHTHALEN 2 YL) 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 BENZYL 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 [(1,1' BIPHENYL) 4 YL] 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; 4 [2 (BENZYLOXY)PHENYL] 1 PENTYL 1H IMIDAZOL 2 AMINE; 4 [2 (BENZYLOXY)PHENYL] 1 PENTYL 1H IMIDAZOL 2 AMINE HYDROCHLORIDE; ELONGATION FACTOR 2 KINASE; IMIDAZOLE DERIVATIVE; METHYL 4 (2 AMINO 1 PENTYL 1H IMIDAZOL 4 YL)BENZOATE HYDROCHLORIDE; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG; [2 (2 AMINO 1 PENTYL 1H IMIDAZOL 4 YL)PHENYL]METHANOL HYDROCHLORIDE; 1-PENTYL-4-PHENYL-1H-IMIDAZOL-2-AMINE; 2-AMINOIMIDAZOLE; 4-(2-(BENZYLOXY)PHENYL)-1-PENTYL-1H-IMIDAZOL-2-AMINE; CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE; CYTOKINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN KINASE INHIBITOR; TLR8 PROTEIN, HUMAN; TOLL LIKE RECEPTOR 8;

ARTICLE; BLOOD; CELL LINE; CRYSTAL STRUCTURE; EC50; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOASSAY; REPORTER GENE; STRUCTURE ACTIVITY RELATION; AGONISTS; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECTS; METABOLISM; MONOCYTE; MONONUCLEAR CELL; SIGNAL TRANSDUCTION;

CALCIUM-CALMODULIN-DEPENDENT PROTEIN KINASES; CELLS, CULTURED; CYTOKINES; HUMANS; IMIDAZOLES; LEUKOCYTES, MONONUCLEAR; MONOCYTES; NF-KAPPA B; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STRUCTURE-ACTIVITY RELATIONSHIP; TOLL-LIKE RECEPTOR 8;

EID: 84966344064     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.6b00023     Document Type: Article

References (83)

1. Andre, F. E.; Booy, R.; Bock, H. L.; Clemens, J.; Datta, S. K.; John, T. J.; Lee, B. W.; Lolekha, S.; Peltola, H.; Ruff, T. A.; Santosham, M.; Schmitt, H. J. Vaccination greatly reduces disease, disability, death and inequity worldwide Bull. W. H. O. 2008, 86, 140-146 10.2471/BLT.07.040089
2. Levine, M. M.; Robins-Browne, R. Vaccines, global health and social equity Immunol. Cell Biol. 2009, 87, 274-278 10.1038/icb.2009.15
3. Henderson, D. A. The history of smallpox eradication Bull. Hist. Med. 1980, 99-114
4. Henderson, D. A. The eradication of smallpox - an overview of the past, present, and future Vaccine 2011, 29 (Suppl 4) D7-D9 10.1016/j.vaccine.2011.06.080
5. Ohimain, E. I. Recent advances in the development of vaccines for Ebola virus disease Virus Res. 2016, 211, 174-185 10.1016/j.virusres.2015.10.021
6. Sridhar, S. Clinical development of Ebola vaccines Ther. Adv. Vaccines 2015, 3, 125-138 10.1177/2051013615611017
7. Takeuchi, O.; Akira, S. Signaling pathways activated by microorganisms Curr. Opin. Cell Biol. 2007, 19, 185-191 10.1016/j.ceb.2007.02.006
8. Kumagai, Y.; Takeuchi, O.; Akira, S. Pathogen recognition by innate receptors J. Infect. Chemother. 2008, 14, 86-92 10.1007/s10156-008-0596-1
9. Kumagai, Y.; Akira, S. Identification and functions of pattern-recognition receptors J. Allergy Clin. Immunol. 2010, 125, 985-992 10.1016/j.jaci.2010.01.058
10. Medzhitov, R.; Janeway, C. A. J. Innate immunity N. Engl. J. Med. 2000, 343, 338-344 10.1056/NEJM200008033430506
11. Medzhitov, R.; Janeway, C. A. J. Innate immunity: impact on the adaptive immune response Curr. Opin. Immunol. 1997, 9, 4-9 10.1016/S0952-7915(97)80152-5
12. Janeway, C. A. J. Presidential Address to The American Association of Immunologists. The road less traveled by: the role of innate immunity in the adaptive immune response J. Immunol. 1998, 161, 539-544
13. Aimanianda, V.; Haensler, J.; Lacroix-Desmazes, S.; Kaveri, S. V.; Bayry, J. Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants Trends Pharmacol. Sci. 2009, 30, 287-295 10.1016/j.tips.2009.03.005
14. Kool, M.; Soullie, T.; van Nimwegen, M.; Willart, M. A.; Muskens, F.; Jung, S.; Hoogsteden, H. C.; Hammad, H.; Lambrecht, B. N. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells J. Exp. Med. 2008, 205, 869-882 10.1084/jem.20071087
15. Tagliabue, A.; Rappuoli, R. Vaccine adjuvants: the dream becomes real Hum. Vaccines 2008, 4, 347-349 10.4161/hv.4.5.6438
16. Esposito, S.; Birlutiu, V.; Jarcuska, P.; Perino, A.; Man, S. C.; Vladareanu, R.; Meric, D.; Dobbelaere, K.; Thomas, F.; Descamps, D. Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the standard dosing schedule in healthy women aged 15 to 25 years: results from a randomized study Pediatr. Infect. Dis. J. 2011, 30, e49-e55 10.1097/INF.0b013e318206c26e
17. Garcon, N.; Segal, L.; Tavares, F.; Van Mechelen, M. The safety evaluation of adjuvants during vaccine development: The AS04 experience Vaccine 2011, 29, 4453-4459 10.1016/j.vaccine.2011.04.046
18. Hoffmann, J.; Akira, S. Innate immunity Curr. Opin. Immunol. 2013, 25, 1-3 10.1016/j.coi.2013.01.008
19. Kawai, T.; Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat. Immunol. 2010, 11, 373-384 10.1038/ni.1863
20. Loo, Y. M.; Gale, M., Jr. Immune signaling by RIG-I-like receptors Immunity 2011, 34, 680-692 10.1016/j.immuni.2011.05.003
21. Kersse, K.; Bertrand, M. J.; Lamkanfi, M.; Vandenabeele, P. NOD-like receptors and the innate immune system: coping with danger, damage and death Cytokine Growth Factor Rev. 2011, 22, 257-276 10.1016/j.cytogfr.2011.09.003
22. Clarke, T. B.; Weiser, J. N. Intracellular sensors of extracellular bacteria Immunol. Rev. 2011, 243, 9-25 10.1111/j.1600-065X.2011.01039.x
23. Unterholzner, L. The interferon response to intracellular DNA: why so many receptors? Immunobiology 2013, 218, 1312-1321 10.1016/j.imbio.2013.07.007
24. Danilchanka, O.; Mekalanos, J. J. Cyclic dinucleotides and the innate immune response Cell 2013, 154, 962-970 10.1016/j.cell.2013.08.014
25. Barber, G. N. Cytoplasmic DNA innate immune pathways Immunol. Rev. 2011, 243, 99-108 10.1111/j.1600-065X.2011.01051.x
26. Salunke, D. B.; Shukla, N. M.; Yoo, E.; Crall, B. M.; Balakrishna, R.; Malladi, S. S.; David, S. A. Structure-activity relationships in human Toll-like receptor 2-specific monoacyl lipopeptides J. Med. Chem. 2012, 55, 3353-3363 10.1021/jm3000533
27. Salunke, D. B.; Connelly, S. W.; Shukla, N. M.; Hermanson, A. R.; Fox, L. M.; David, S. A. Design and development of stable, water-soluble, human Toll-like receptor 2 specific monoacyl lipopeptides as candidate vaccine adjuvants J. Med. Chem. 2013, 56, 5885-5900 10.1021/jm400620g
28. Wu, W.; Li, R.; Malladi, S. S.; Warshakoon, H. J.; Kimbrell, M. R.; Amolins, M. W.; Ukani, R.; Datta, A.; David, S. A. Structure-activity relationships in toll-like receptor-2 agonistic diacylthioglycerol lipopeptides J. Med. Chem. 2010, 53, 3198-3213 10.1021/jm901839g
29. Shukla, N. M.; Kimbrell, M. R.; Malladi, S. S.; David, S. A. Regioisomerism-dependent TLR7 agonism and antagonism in an imidazoquinoline Bioorg. Med. Chem. Lett. 2009, 19, 2211-2214 10.1016/j.bmcl.2009.02.100
30. Shukla, N. M.; Malladi, S. S.; Mutz, C. A.; Balakrishna, R.; David, S. A. Structure-activity relationships in human toll-like receptor 7-active imidazoquinoline analogues J. Med. Chem. 2010, 53, 4450-4465 10.1021/jm100358c
31. Shukla, N. M.; Mutz, C. A.; Ukani, R.; Warshakoon, H. J.; Moore, D. S.; David, S. A. Syntheses of fluorescent imidazoquinoline conjugates as probes of Toll-like receptor 7 Bioorg. Med. Chem. Lett. 2010, 20, 6384-6386 10.1016/j.bmcl.2010.09.093
32. Shukla, N. M.; Lewis, T. C.; Day, T. P.; Mutz, C. A.; Ukani, R.; Hamilton, C. D.; Balakrishna, R.; David, S. A. Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound toll-like receptor-7 agonistic imidazoquinolines Bioorg. Med. Chem. Lett. 2011, 21, 3232-3236 10.1016/j.bmcl.2011.04.050
33. Shukla, N. M.; Malladi, S. S.; Day, V.; David, S. A. Preliminary evaluation of a 3H imidazoquinoline library as dual TLR7/TLR8 antagonists Bioorg. Med. Chem. 2011, 19, 3801-3811 10.1016/j.bmc.2011.04.052
34. Shukla, N. M.; Mutz, C. A.; Malladi, S. S.; Warshakoon, H. J.; Balakrishna, R.; David, S. A. Toll-like receptor (TLR)-7 and -8 modulatory activities of dimeric imidazoquinolines J. Med. Chem. 2012, 55, 1106-1116 10.1021/jm2010207
35. Shukla, N. M.; Salunke, D. B.; Balakrishna, R.; Mutz, C. A.; Malladi, S. S.; David, S. A. Potent adjuvanticity of a pure TLR7-agonistic imidazoquinoline dendrimer PLoS One 2012, 7, e43612 10.1371/journal.pone.0043612
36. Yoo, E.; Crall, B. M.; Balakrishna, R.; Malladi, S. S.; Fox, L. M.; Hermanson, A. R.; David, S. A. Structure-activity relationships in Toll-like receptor 7 agonistic 1H-imidazo[4,5-c]pyridines Org. Biomol. Chem. 2013, 11, 6526-6545 10.1039/c3ob40816g
37. Yoo, E.; Salunke, D. B.; Sil, D.; Guo, X.; Salyer, A. C.; Hermanson, A. R.; Kumar, M.; Malladi, S. S.; Balakrishna, R.; Thompson, W. H.; Tanji, H.; Ohto, U.; Shimizu, T.; David, S. A. Determinants of activity at human Toll-like receptors 7 and 8: quantitative structure-activity relationship (QSAR) of diverse heterocyclic scaffolds J. Med. Chem. 2014, 57, 7955-7970 10.1021/jm500744f
38. Salunke, D. B.; Yoo, E.; Shukla, N. M.; Balakrishna, R.; Malladi, S. S.; Serafin, K. J.; Day, V. W.; Wang, X.; David, S. A. Structure-activity relationships in human Toll-like receptor 8-active 2,3-diamino-furo[2,3-c]pyridines J. Med. Chem. 2012, 55, 8137-8151 10.1021/jm301066h
39. Kokatla, H. P.; Yoo, E.; Salunke, D. B.; Sil, D.; Ng, C. F.; Balakrishna, R.; Malladi, S. S.; Fox, L. M.; David, S. A. Toll-like receptor-8 agonistic activities in C2, C4, and C8 modified thiazolo[4,5-c]quinolines Org. Biomol. Chem. 2013, 11, 1179-1198 10.1039/c2ob26705e
40. Kokatla, H. P.; Sil, D.; Malladi, S. S.; Balakrishna, R.; Hermanson, A. R.; Fox, L. M.; Wang, X.; Dixit, A.; David, S. A. Exquisite selectivity for human toll-like receptor 8 in substituted furo[2,3-c]quinolines J. Med. Chem. 2013, 56, 6871-6885 10.1021/jm400694d
41. Kokatla, H. P.; Sil, D.; Tanji, H.; Ohto, U.; Malladi, S. S.; Fox, L. M.; Shimizu, T.; David, S. A. Structure-based design of novel human Toll-like receptor 8 agonists ChemMedChem 2014, 9, 719-723 10.1002/cmdc.201300573
42. Beesu, M.; Malladi, S. S.; Fox, L. M.; Jones, C. D.; Dixit, A.; David, S. A. Human Toll-like receptor 8-selective agonistic activities in 1-alkyl-1H-benzimidazol-2-amines J. Med. Chem. 2014, 57, 7325-7341 10.1021/jm500701q
43. Agnihotri, G.; Ukani, R.; Malladi, S. S.; Warshakoon, H. J.; Balakrishna, R.; Wang, X.; David, S. A. Structure-activity relationships in nucleotide oligomerization domain 1 (Nod1) agonistic gamma-glutamyldiaminopimelic acid derivatives J. Med. Chem. 2011, 54, 1490-1510 10.1021/jm101535e
44. Ukani, R.; Lewis, T. C.; Day, T. P.; Wu, W.; Malladi, S. S.; Warshakoon, H. J.; David, S. A. Potent adjuvantic activity of a CCR1-agonistic bis-quinoline Bioorg. Med. Chem. Lett. 2012, 22, 293-295 10.1016/j.bmcl.2011.11.014
45. Bekeredjian-Ding, I.; Roth, S. I.; Gilles, S.; Giese, T.; Ablasser, A.; Hornung, V.; Endres, S.; Hartmann, G. T cell-independent, TLR-induced IL-12p70 production in primary human monocytes J. Immunol. 2006, 176, 7438-7446 10.4049/jimmunol.176.12.7438
46. Warshakoon, H. J.; Hood, J. D.; Kimbrell, M. R.; Malladi, S.; Wu, W. Y.; Shukla, N. M.; Agnihotri, G.; Sil, D.; David, S. A. Potential adjuvantic properties of innate immune stimuli Hum. Vaccines 2009, 5, 381-394 10.4161/hv.5.6.8175
47. Bohnenkamp, H. R.; Papazisis, K. T.; Burchell, J. M.; Taylor-Papadimitriou, J. Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses Cell. Immunol. 2007, 247, 72-84 10.1016/j.cellimm.2007.07.008
48. Philbin, V. J.; Levy, O. Immunostimulatory activity of Toll-like receptor 8 agonists towards human leucocytes: basic mechanisms and translational opportunities Biochem. Soc. Trans. 2007, 35, 1485-1491 10.1042/BST0351485
49. Saruta, M.; Michelsen, K. S.; Thomas, L. S.; Yu, Q. T.; Landers, C. J.; Targan, S. R. TLR8-mediated activation of human monocytes inhibits TL1A expression Eur. J. Immunol. 2009, 39, 2195-2202 10.1002/eji.200939216
50. Beesu, M.; Caruso, G.; Salyer, A. C.; Khetani, K. K.; Sil, D.; Weerasinghe, M.; Tanji, H.; Ohto, U.; Shimizu, T.; David, S. A. Structure-based design of human TLR8-specific agonists with augmented potency and adjuvanticity J. Med. Chem. 2015, 58, 7833-7849 10.1021/acs.jmedchem.5b01087
51. Kang, J. Y.; Lee, J. O. Structural biology of the Toll-like receptor family Annu. Rev. Biochem. 2011, 80, 917-941 10.1146/annurev-biochem-052909-141507
52. Botos, I.; Segal, D. M.; Davies, D. R. The structural biology of Toll-like receptors Structure 2011, 19, 447-459 10.1016/j.str.2011.02.004
53. Hatzakis, N. S. Single molecule insights on conformational selection and induced fit mechanism Biophys. Chem. 2014, 186, 46-54 10.1016/j.bpc.2013.11.003
54. Amaravadhi, H.; Baek, K.; Yoon, H. S. Revisiting de novo drug design: receptor based pharmacophore screening Curr. Top. Med. Chem. 2014, 14, 1890-1898 10.2174/1568026614666140929115506
55. Ermolat'ev, D. S.; Babaev, E. V.; Van der Eycken, E. V. Efficient one-pot, two-step, microwave-assisted procedure for the synthesis of polysubstituted 2-aminoimidazoles Org. Lett. 2006, 8, 5781-5784 10.1021/ol062421c
56. Tanji, H.; Ohto, U.; Shibata, T.; Miyake, K.; Shimizu, T. Structural reorganization of the Toll-like receptor 8 dimer induced by agonistic ligands Science 2013, 339, 1426-1429 10.1126/science.1229159
57. Scholfield, M. R.; Zanden, C. M.; Carter, M.; Ho, P. S. Halogen bonding (X-bonding): a biological perspective Protein Sci. 2013, 22, 139-152 10.1002/pro.2201
58. Auffinger, P.; Hays, F. A.; Westhof, E.; Ho, P. S. Halogen bonds in biological molecules Proc. Natl. Acad. Sci. U. S. A. 2004, 101, 16789-16794 10.1073/pnas.0407607101
59. Merlot, A. M.; Kalinowski, D. S.; Richardson, D. R. Unraveling the mysteries of serum albumin-more than just a serum protein Front. Physiol. 2014, 5, 299 10.3389/fphys.2014.00299
60. Bohnert, T.; Gan, L. S. Plasma protein binding: from discovery to development J. Pharm. Sci. 2013, 102, 2953-2994 10.1002/jps.23614
61. Huang, Z.; Ung, T. Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics Curr. Drug Metab. 2013, 14, 226-238 10.2174/138920013804870709
62. MacIntyre, A. C.; Cutler, D. J. The potential role of lysosomes in tissue distribution of weak bases Biopharm. Drug Dispos. 1988, 9, 513-526 10.1002/bod.2510090602
63. Malito, E.; Bursulaya, B.; Chen, C.; Lo, S. P.; Picchianti, M.; Balducci, E.; Biancucci, M.; Brock, A.; Berti, F.; Bottomley, M. J.; Nissum, M.; Costantino, P.; Rappuoli, R.; Spraggon, G. Structural basis for lack of toxicity of the diphtheria toxin mutant CRM197 Proc. Natl. Acad. Sci. U. S. A. 2012, 109, 5229-5234 10.1073/pnas.1201964109
64. Wu, T. Y.; Singh, M.; Miller, A. T.; De Gregorio, E.; Doro, F.; D'Oro, U.; Skibinski, D. A.; Mbow, M. L.; Bufali, S.; Herman, A. E.; Cortez, A.; Li, Y.; Nayak, B. P.; Tritto, E.; Filippi, C. M.; Otten, G. R.; Brito, L. A.; Monaci, E.; Li, C.; Aprea, S.; Valentini, S.; Calabromicron, S.; Laera, D.; Brunelli, B.; Caproni, E.; Malyala, P.; Panchal, R. G.; Warren, T. K.; Bavari, S.; O'Hagan, D. T.; Cooke, M. P.; Valiante, N. M. Rational design of small molecules as vaccine adjuvants Sci. Transl. Med. 2014, 6, 263ra160 10.1126/scitranslmed.3009980
65. Casale, T. B.; Kessler, J.; Romero, F. A. Safety of the intranasal toll-like receptor 4 agonist CRX-675 in allergic rhinitis Ann. Allergy, Asthma, Immunol. 2006, 97, 454-456 10.1016/S1081-1206(10)60934-9
66. Greiff, L.; Cervin, A.; Ahlstrom-Emanuelsson, C.; Almqvist, G.; Andersson, M.; Dolata, J.; Eriksson, L.; Hogestatt, E.; Kallen, A.; Norlen, P.; Sjolin, I. L.; Widegren, H. Repeated intranasal TLR7 stimulation reduces allergen responsiveness in allergic rhinitis Respir. Res. 2012, 13, 53 10.1186/1465-9921-13-53
67. Matsui, H.; Tomizawa, H.; Eiho, K.; Kashiwazaki, Y.; Edwards, S.; Biffen, M.; Bell, J. P.; Bahl, A.; Leishman, A. J.; Murray, C. M.; Takaku, H.; Ueda, Y. Mechanism of action of inhibition of allergic immune responses by a novel antedrug TLR7 agonist J. Immunol. 2012, 189, 5194-5205 10.4049/jimmunol.1101331
68. Kaufman, E. H.; Jacoby, D. B. Upping the antedrug: is a novel anti-inflammatory Toll-like receptor 7 agonist also a bronchodilator? Br. J. Pharmacol. 2012, 166, 569-572 10.1111/j.1476-5381.2011.01758.x
69. Biffen, M.; Matsui, H.; Edwards, S.; Leishman, A. J.; Eiho, K.; Holness, E.; Satterthwaite, G.; Doyle, I.; Wada, H.; Fraser, N. J.; Hawkins, S. L.; Aoki, M.; Tomizawa, H.; Benjamin, A. D.; Takaku, H.; McInally, T.; Murray, C. M. Biological characterization of a novel class of toll-like receptor 7 agonists designed to have reduced systemic activity Br. J. Pharmacol. 2012, 166, 573-586 10.1111/j.1476-5381.2011.01790.x
70. Han, J.; Lee, J. D.; Bibbs, L.; Ulevitch, R. J. A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells Science 1994, 265, 808-811 10.1126/science.7914033
71. Pearson, G.; Robinson, F.; Beers Gibson, T.; Xu, B. E.; Karandikar, M.; Berman, K.; Cobb, M. H. Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions Endocr. Rev. 2001, 22, 153-183 10.1210/edrv.22.2.0428
72. Mellman, I.; Fuchs, R.; Helenius, A. Acidification of the endocytic and exocytic pathways Annu. Rev. Biochem. 1986, 55, 663-700 10.1146/annurev.bi.55.070186.003311
73. Feldman, R. I.; Wu, J. M.; Polokoff, M. A.; Kochanny, M. J.; Dinter, H.; Zhu, D.; Biroc, S. L.; Alicke, B.; Bryant, J.; Yuan, S.; Buckman, B. O.; Lentz, D.; Ferrer, M.; Whitlow, M.; Adler, M.; Finster, S.; Chang, Z.; Arnaiz, D. O. Novel small molecule inhibitors of 3-phosphoinositide-dependent kinase-1 J. Biol. Chem. 2005, 280, 19867-19874 10.1074/jbc.M501367200
74. Clark, K.; Plater, L.; Peggie, M.; Cohen, P. Use of the pharmacological inhibitor BX795 to study the regulation and physiological roles of TBK1 and IkappaB kinase epsilon: a distinct upstream kinase mediates Ser-172 phosphorylation and activation J. Biol. Chem. 2009, 284, 14136-14146 10.1074/jbc.M109.000414
75. +(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis Antimicrob. Agents Chemother. 2006, 50, 4214-4216 10.1128/AAC.00617-06
76. Sekellick, M. J.; Carra, S. A.; Bowman, A.; Hopkins, D. A.; Marcus, P. I. Transient resistance of influenza virus to interferon action attributed to random multiple packaging and activity of NS genes J. Interferon Cytokine Res. 2000, 20, 963-970 10.1089/10799900050198408
77. Sordella, R.; Bell, D. W.; Haber, D. A.; Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways Science 2004, 305, 1163-1167 10.1126/science.1101637
78. Ostinowski, Z. M. W. Processing of X-ray diffraction data collected in oscillation mode Methods Enzymol. 1997, 276, 307-326 10.1016/S0076-6879(97)76066-X
79. Vagin, A.; Teplyakov, A. Molecular replacement with MOLREP Acta Crystallogr., Sect. D: Biol. Crystallogr. 2010, 66, 22-25 10.1107/S0907444909042589
80. Emsley, P.; Cowtan, K. Coot: model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132 10.1107/S0907444904019158
81. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255 10.1107/S0907444996012255
82. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. Procheck: a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 1993, 26, 283-291 10.1107/S0021889892009944
83. Hood, J. D.; Warshakoon, H. J.; Kimbrell, M. R.; Shukla, N. M.; Malladi, S.; Wang, X.; David, S. A. Immunoprofiling toll-like receptor ligands: Comparison of immunostimulatory and proinflammatory profiles in ex vivo human blood models Hum. Vaccines 2010, 6, 322-3355 10.4161/hv.6.4.10866